Cytodyn Inc (CYDY)

[Saltz]

COULD is the operative word when referring to first Q 2017. To me that means best case scenario not worst case scenario. Nader is going to communicate best case and we need to be prepared for Q2. This is the nature of this investment. Missing or delaying timelines kill SP while exceeding expectations will create urgency as the approval and monetizing of Pro-140 are derisked. Put a couple of exceeding expectations milestones together and the SP will run away. We as shareholders are longing for that point in time. My attention is on speed of enrollment for both Adjunct and Mono. If Pro-140 is everything we as shareholders believe it is enrollment should be like a dam breaking-flooded with patients. 38 sites and revised protocol - EXECUTE and exceed timeline expectations.